CD25 appears non essential for human peripheral T(reg) maintenance in vivo
- PMID: 20689592
- PMCID: PMC2912775
- DOI: 10.1371/journal.pone.0011784
CD25 appears non essential for human peripheral T(reg) maintenance in vivo
Abstract
Background: IL-2 has been reported to be critical for peripheral T(reg) survival in mouse models. Here, we examined T(reg) maintenance in a series of paediatric liver transplant recipients who received basiliximab, a therapeutic anti-CD25 monoclonal antibody.
Methodology/principal findings: FoxP3+ CD4 T cells were analyzed by flow cytometry before liver grafting and more than 9 months later. We found that in vivo CD25 blockade did not lead to T(reg) depletion: the proportion of FoxP3+ cells among CD4 T cells and the level of FoxP3 expression were both unchanged. IL-2Rbeta expression was enhanced in FoxP3+ cells both before and after basiliximab treatment, while the level of IL-2Rgamma expression was similar in T(regs) and non-T(regs). No significant change in the weak or absent expression of IL-7Ralpha and IL-15Ralpha expression on FoxP3+ cells was observed. Although the proportion of FoxP3+ cells among CD4 T cells did not vary, food allergies occurred more rapidly after liver grafting in patients who received basiliximab, raising questions as to T(reg) functionality in vivo in the absence of functional CD25.
Conclusions: CD25 appears non essential for human T(reg) peripheral maintenance in vivo. However, our results raise questions as to T(reg) functionality after therapeutic CD25 targeting.
Conflict of interest statement
Figures


Similar articles
-
Short-term anti-CD25 monoclonal antibody administration down-regulated CD25 expression without eliminating the neogenetic functional regulatory T cells in kidney transplantation.Clin Exp Immunol. 2009 Mar;155(3):496-503. doi: 10.1111/j.1365-2249.2008.03847.x. Epub 2009 Jan 7. Clin Exp Immunol. 2009. PMID: 19141125 Free PMC article. Clinical Trial.
-
Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients.Clin Exp Immunol. 2012 May;168(2):251-9. doi: 10.1111/j.1365-2249.2012.04571.x. Clin Exp Immunol. 2012. PMID: 22471287 Free PMC article.
-
Impact of Basiliximab on regulatory T-cells early after kidney transplantation: down-regulation of CD25 by receptor modulation.Transpl Int. 2010 May 1;23(5):514-23. doi: 10.1111/j.1432-2277.2009.01013.x. Epub 2009 Nov 30. Transpl Int. 2010. PMID: 19951265
-
CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus.Arch Dermatol Res. 2009 Jan;301(1):71-81. doi: 10.1007/s00403-008-0891-9. Epub 2008 Nov 5. Arch Dermatol Res. 2009. PMID: 18985367 Review.
-
Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases.Nat Rev Immunol. 2010 Dec;10(12):849-59. doi: 10.1038/nri2889. Nat Rev Immunol. 2010. PMID: 21107346 Free PMC article. Review.
Cited by
-
Functional improvement of regulatory T cells from rheumatoid arthritis subjects induced by capsular polysaccharide glucuronoxylomannogalactan.PLoS One. 2014 Oct 22;9(10):e111163. doi: 10.1371/journal.pone.0111163. eCollection 2014. PLoS One. 2014. PMID: 25338013 Free PMC article.
-
Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new.Clin Dev Immunol. 2012;2012:823085. doi: 10.1155/2012/823085. Epub 2012 Jun 14. Clin Dev Immunol. 2012. PMID: 22761634 Free PMC article. Review.
-
T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives.Mediators Inflamm. 2015;2015:243723. doi: 10.1155/2015/243723. Epub 2015 Apr 28. Mediators Inflamm. 2015. PMID: 26060357 Free PMC article. Review.
-
Administration of a nondepleting anti-CD25 monoclonal antibody reduces disease severity in mice infected with Trypanosoma cruzi.Eur J Microbiol Immunol (Bp). 2014 Jun;4(2):128-37. doi: 10.1556/EuJMI.4.2014.2.6. Epub 2014 May 21. Eur J Microbiol Immunol (Bp). 2014. PMID: 24883199 Free PMC article.
-
Effect of induction therapy on the expression of molecular markers associated with rejection and tolerance.BMC Nephrol. 2015 Aug 19;16:146. doi: 10.1186/s12882-015-0141-2. BMC Nephrol. 2015. PMID: 26286066 Free PMC article.
References
-
- Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation. 1999;67:276–284. - PubMed
-
- Du J, Yang H, Zhang D, Wang J, Guo H, et al. Structural basis for the blockage of IL-2 signaling by therapeutic antibody basiliximab. J Immunol. 2010;184:1361–1368. - PubMed
-
- Binder M, Vogtle FN, Michelfelder S, Muller F, Illerhaus G, et al. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res. 2007;67:3518–3523. - PubMed
-
- Rickert M, Boulanger MJ, Goriatcheva N, Garcia KC. Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin-2 and its alpha, beta, and gamma(c) receptors. J Mol Biol. 2004;339:1115–1128. - PubMed
-
- Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity. 2009;30:626–635. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials